Antibiotics currently available

The penicillins and cephalosporins, collectively known as beta-lactam antibiotics, are among the most widely used and valuable antibiotics currently available. Ben-zylpenicilhn (penicillin G) and phenoxymethylpenicillin (penicillin V) are derived from Penicillium molds by fermentation, while half-synthetic penicillins are derived by chemical modification of the penicillin nucleus, 6-aminopenicillanic acid (6-APA), itself obtained either by splitting the side chain from benzylpenicillin through an enzymatic process or via a chemical deacylation reaction. 

The anthrax bioterrorist attacks that followed the events of September 11th 2001 resulted in a renewed interest BadUus anthracis, the causative agent of this disease. Research has focused on the development of better vaccines than the one currently available. It has been estimated that the aerosolized release of 100 kg of anthrax spores upwind of Washington DC would cause mortalities of 130,000-3,000,000 [63]. Nonetheless, wild-type Bacillus anthracis is susceptible to conventional antibiotics, including penicillin, oxyfloxacin and ciprofloxacin. The problem lies not with the bacterial infection itself, but with three proteins released by the bacteria - protective antigen (PA, 83 kDa), lethal factor (LF, 90 kDa) and edema factor (EF, 89 kDa) -known as anthrax toxins [63]. 

Abstract Resistance to modern antibiotics is currently a major health concern in treating infectious diseases. Abuse, overuse, and misuse of antibiotics in treating human illness have caused the pathogens to develop resistance through a process known as natural selection. The most common mechanism of resistance to -lactam antibiotics is the production of /3-lactamases, which destroy -lactam antibiotics before they reach the bacterial target. Over the last two decades, combination therapy involving treatment with a -lactam antibiotic and a /3-lactamase inhibitor has become very successful in controlling -lactamase-mediated bacterial resistance. Currently available inhibitors like... 

Bacterial resistance to antibiotics is an emerging public health crisis. The prevalence of pathogens resistant to currently available antibiotics continues to grow annually. Two million patients in the U.S. acquire an infection during a hospital stay and approximately 90,000 of these patients die each year as a result of the infection [1]. More than 70% of hospital-acquired infections are now resistant to... 

Prophylaxis For asymptomatic patients exposed to plague aerosol, or to a patient with suspected pneumonic plague, provide doxycycline at 100 mg orally twice daily for seven days, or for the duration of risk of exposure plus one week. Alternative antibiotics include ciprofloxacin, tetracycline, or chloramphenicol. No vaccine is currently available for plague propylaxis. The previously available licensed, killed vaccine was effective against bubonic plague, but not against aerosol exposure. 

Treatment — A number of antibiotics are available including doxycycline combined with rifampin, and ofloxacin combined with rifampin. Vaccines for animal use directed against B. melitensis and B. abortus have proven very successful. An effective vaccine for human use against B. suis is currently under development.3... 

Carbapenems are synthetic p-lactam antibiotics that differ from the penicillins in that the sulfur atom of the thiazolidine ring (Figure 30.9) has been externalized and replaced by a carbon atom. Imipenem [i mi PEN em] is the only drug of this group currently available. 

Inhaled corticosteroids should be prescribed for patients with an FEVi of 50% predicted or less, who have two or more exacerbations needing treatment with antibiotics or oral corticosteroids a year. Warn patients about the possible risk of osteoporosis and other side effects of high-dose inhaled corticosteroids. None of the inhaled corticosteroids currently available is licensed alone for use in COPD. 

The overwhelming majority of semisynthetic beta-lactam antibiotics, the penicillins and cephalosporin, currently available to physicians trace their origins to the intense research effort devoted to this field several decades ago. The emergence of pathogens resistant to those antibiotics has led some laboratories to revisit this field. The modified cephalosporin ceftobiprole (220), a compound with a rather complex extended side chain, has shown activity in the clinic against some strains of multidrug resistant bacteria. The synthesis starts with the well-precedented acylation of the of the cephalosporin (215), available in several steps from the commercially available 7-acetoxy cephalosporanic acid, with the activated... 

Thus, though mycobacterial infections are difficult to treat under even the best of circumstances using currently available drugs, novel antibiotics targeting the biosynthesis of the unique mycobacterial cell wall structures show promise for clinical development. Further characterization of the enzymes involved in the biosynthesis of cell wall structures will facilitate the development of such antibiotics. Furthermore, studies of the cell wall biosynthetic pathways will likely uncover new potential targets for drug design efforts. 

Infections can usually be treated with penicillinase-resistant B-lactams. Infections acquired in the hospital are often antibiotic resistant strains and can only be treated with vanomycin. Vaccines are not currently available. 

Currently available CSPs were developed for conventional HPLC analytical applications the wader the diversity of chemical stmctures that a particular phase could resolve, the better. For a production-scale SMB resolution, which will be for one specific compound, such a property is unnecessary. Furthermore, the physical characteristics (particle size, etc.) required for SMB are different from those needed for HPLC. It is reasonable to expect that new or modified and perhaps tailored CSPs will be developed that will be significantly cheaper than current products. Had such CSPs been available in the 60s, it is likely that antibiotic side chains would have been produced using SMB instead of by classical resolution. 

Answer B. Indications for the use of penicillin G are currently limited for a number of reasons. The drug has a narrow spectrum, is susceptible to beta-lactamases, and may cause hypersensitivity, and alternative antibiotics are available. However, penicillin G remains the drug of choice in syphilis, usually given IM as benzathine penicillin G, but as the Na or K salt IV in neurosyphilis. What would you do for patients who are highly allergic to penicillins (Consider tetracyclines, or possibly desensitization.)... 

TREATMENT OF NONRESPONSIVE INFECTIONS Most viral diseases are self-limited and do not respond to any of the currently available anti-infective compounds. Thus, antibiotic therapy of at least 90% of infections of the upper respiratory tract and many GI infections is ineffective. 

---